PleoPharma Closes $36M Series B Financing Round

By
mg Magazine Newswire
-
PleoPharma Inc. Logo

PHOENIXVILLE, Pa. — PleoPharma Inc., a privately held company focused on finding treatments for cannabis-related health issues, closed a $36M Series B financing round.

PleoPharma will use the proceeds to advance its lead asset, PP-01, an investigational product for treating cannabis use disorder.

Advertisement
President Donald Trump delivers remarks after signing an executive order to reclassify marijuana, directing federal agencies to expedite cannabis rescheduling from Schedule I to Schedule III.

SuperVision Partners LLC served as the lead placement agent for the offering along with Castle Hill Capital Partners Inc.

Related Articles:

FundCanna founder and CEO Adam Stettner Adam Stettner is Reshaping Finance portraits of purposeHow Women Cannabis Leaders Are Creating a More Equitable Future Rebecca Colett, CEO of Calyxeum, smiling in a cannabis cultivation facility while wearing a "Support Black Growers" hoodie. Why Women Are the Power Players in Cannabis — As Consumers and Entrepreneurs
Advertisement
President Donald Trump delivers remarks after signing an executive order to reclassify marijuana, directing federal agencies to expedite cannabis rescheduling from Schedule I to Schedule III.